User: Violet: Healthcare: slopechart_SYK.jpg

SYK weekly. 
4/28/22

The Bear cave reported on 10Apr22: 
Spruce Point Capital published a 57,201-word presentation on Stryker Corporation (NYSE: SYK — $102 billion), a large medical technologies company. Spruce Point criticized the company’s “track record of paying rich premiums for acquisition targets” and highlighted that its total debt is currently ~5x EBITDA. In addition, Spruce Point conducted a “behavioral analysis of Stryker management” and believes the company “often delays bad news as long as possible.” As an example, Spruce Point cited a $500 million project to integrate various Enterprise Resource Planning software systems that was ultimately written off. Spruce Point concluded, 
“In light of our concerns about the accuracy of Stryker’s financial reporting, and tactics it’s using to embellish results, we believe holding shares at this level represents a poor risk/reward.” 4/28/22

@Violet I pay attention when multiple sources converge on a target. 4/28/22

So many more people I know getting various joint replacements, of which Stryker dominates the market. 
 
This is an aging first world problem play. 
 
Yes, I agree it's awfully expensive. 4/28/22